{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-284089","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-06-26T13:18:21+00:00","discovered_at":"2026-06-26T13:19:00.241889+00:00","generated_at":"2026-06-26T13:19:15.378930+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026","bullets":["Stockholders approved reverse split on June 11, 2026; board set ratio at 1-for-20.","Certificate of Amendment filed with Delaware Secretary of State on June 26, 2026; effective June 29 at 11:59 pm ET.","Pre-split shares outstanding: 19,559,257; post-split approx 977,963; CUSIP changes to 22053A305.","Ticker remains QNCX; options and warrants proportionally adjusted; fractional shares cashed out."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-284089","json":"https://secwatch.observer/filing/0001193125-26-284089.json","markdown":"https://secwatch.observer/filing/0001193125-26-284089.md","text":"https://secwatch.observer/filing/0001193125-26-284089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526284089/0001193125-26-284089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526284089/d168420d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T13:19:15.378930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}